Determining Patient Risk by Differentiating Aggressive from Nonaggressive Prostate Cancer Using a Serum Protein Risk Stratification Test

• Forschungsstelle: INNOSUISSE
• Projektnummer: 16771.3 PFLS-LS
• Projekttitel Englisch: Determining Patient Risk by Differentiating Aggressive from Nonaggressive Prostate Cancer Using a Serum Protein Risk Stratification Test: MIP: ProteoMediX AG

Kurzbeschreibung (Deutsch)

Determining Patient Risk by Differentiating Aggressive from Nonaggressive Prostate Cancer Using a Serum Protein Risk Stratification Test

Kurzbeschreibung (Englisch)

Determining Patient Risk by Differentiating Aggressive from Nonaggressive Prostate Cancer Using a Serum Protein Risk Stratification Test: MIP: ProteoMediX AG

Abstract (Deutsch)

The goal of the interdisciplinary ProteoMediX/ETHZ/USZ/FHNW project is to develop an immunoassay-based risk stratification test (PMX-Px) for the prognosis of patients diagnosed|with localized prostate cancer (PCa) by using Mass Spectrometry-GUided Immunoassay DEvelopment (MS-GUIDE). A commercially available kit in the context of personalized|medicine will provide doctors and patients with a tool supporting them in their decision making in between prostatectomy or active surveillance for patients with localized|PCa.

Abstract (Englisch)

The goal of the interdisciplinary ProteoMediX/ETHZ/USZ/FHNW project is to develop an immunoassay-based risk stratification test (PMX-Px) for the prognosis of patients diagnosed|with localized prostate cancer (PCa) by using Mass Spectrometry-GUided Immunoassay DEvelopment (MS-GUIDE). A commercially available kit in the context of personalized|medicine will provide doctors and patients with a tool supporting them in their decision making in between prostatectomy or active surveillance for patients with localized|PCa.